Interleukin-17A-Induced Human Mesenchymal Stem Cells Are Superior Modulators of Immunological Function

Stem Cells

Volumn 33, Issue 9, 2015, Pages 2850-2863

  Sivanathan, Kisha Nandini ^a,b,c   Rojas Canales, Darling M ^a,b   Hope, Christopher M ^a,b   Krishnan, Ravi ^a   Carroll, Robert P ^b,d   Gronthos, Stan ^a,c   Grey, Shane T ^e   Coates, Patrick T ^a,b,c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Centre for Clinical and Experimental Transplantation   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Immunomodulation; Interferon gamma; Interleukin 17A; Mesenchymal stem cells; Regulatory T cells; T cells

Indexed keywords

CD4 ANTIGEN; CYCLOOXYGENASE 1; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; PHYTOHEMAGGLUTININ; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; IL17A PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; CELL SURFACE; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM;

CELLS, CULTURED; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84940467141     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2075     Document Type: Article

References (92)

1. Gronthos S, Zannettino ACW, Hay SJ, et al., Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003; 116: 1827-1835.
2. Caplan AI, Dennis JE,. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084.
3. Togel F, Hu Z, Weiss K, et al., Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31-F42.
4. Psaltis PJ, Paton S, See F, et al., Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 2010; 223: 530-540.
5. Kortesidis A, Zannettino A, Isenmann S, et al., Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 2005; 105: 3793-3801.
6. Ries C, Egea V, Karow M, et al., MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines. Blood 2007; 109: 4055-4063.
7. Wynn RF, Hart CA, Corradi-Perini C, et al., A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004; 104: 2643-2645.
8. Zou Z, Zhang Y, Hao L, et al., More insight into mesenchymal stem cells and their effects inside the body. Exp Opin Biol Ther 2010; 10: 215-230.
9. Hematti P,. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev 2008; 22: 262-273.
10. Selmani Z, Naji A, Zidi I, et al., Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.
11. Rasmusson I, Ringden O, Sundberg B, et al., Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213.
12. Augello A, Tasso R, Negrini SM, et al., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490.
13. Ramasamy R, Fazekasova H, Lam EW, et al., Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76.
14. Jung YJ, Ju SY, Yoo ES, et al., MSC-DC interactions: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy 2007; 9: 451-458.
15. Le Blanc K, Rasmusson I, Sundberg B, et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
16. Kebriaei P, Isola L, Bahceci E, et al., Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transp 2009; 15: 804-811.
17. Wise AF, Ricardo SD,. Mesenchymal stem cells in kidney inflammation and repair. Nephrology 2012; 17: 1-10.
18. Longoni B, Szilagyi E, Quaranta P, et al., Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabet Technol Therapeut 2010; 12: 435-446.
19. Tan J, Wu W, Xu X, et al., Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012; 307: 1169-1177.
20. Bartholomew A, Sturgeon C, Siatskas M, et al., Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
21. Sivanathan KN, Gronthos S, Rojas-Canales D, et al., Interferon-gamma modification of mesenchymal stem cells: Implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev 2014; 10: 351-375.
22. Ding Y, Xu D, Feng G, et al., Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 2009; 58: 1797-1806.
23. Di Nicola M, Carlo-Stella C, Magni M, et al., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
24. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
25. Wada N, Bartold PM, Gronthos S,. Human foreskin fibroblasts exert immunomodulatory properties by a different mechanism to bone marrow stromal/stem cells. Stem Cells Dev 2011; 20: 647-659.
26. Lepelletier Y, Lecourt S, Renand A, et al., Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19: 1075-1079.
27. Mougiakakos D, Jitschin R, Johansson CC, et al., The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117: 4826-4835.
28. Djouad F, Charbonnier LM, Bouffi C, et al., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032.
29. Spaggiari GM, Abdelrazik H, Becchetti F, et al., MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
30. Najar M, Raicevic G, Jebbawi F, et al., Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett 2012; 146: 50-56.
31. Opitz CA, Litzenburger UM, Lutz C, et al., Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27: 909-919.
32. Akiyama K, Chen C, Wang D, et al., Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555.
33. Nguyen T, Arthur A, Hayball J, et al., EphB and ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells. Stem Cells Dev 2013; 22: 2751-2764.
34. Xue Q, Luan XY, Gu YZ, et al., The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity Stem Cells Dev 2010; 19: 27-38.
35. Le Blanc K, Rasmusson I, Gotherstrom C, et al., Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand Immunol 2004; 60: 307-315.
36. Batten P, Sarathchandra P, Antoniw JW, et al., Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves. Tissue Eng 2006; 12: 2263-2273.
37. Luz-Crawford P, Kurte M, Bravo-Alegria J, et al., Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013; 4: 65.
38. Hsu WT, Lin CH, Chiang BL, et al., Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-gamma+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol 2013; 190: 2372-2380.
39. Ge W, Jiang J, Arp J, et al., Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
40. English K, Ryan JM, Tobin L, et al., Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
41. Wilczynski JR, Radwan M, Kalinka J,. The characterization and role of regulatory T cells in immune reactions. Front Biosci 2008; 13: 2266-2274.
42. Magenau JM, Qin X, Tawara I, et al., Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transp 2010; 16: 907-914.
43. Shevach EM,. Regulatory T cells in autoimmmunity. Ann Rev Immunol 2000; 18: 423-449.
44. Waldmann H, Hilbrands R, Howie D, et al., Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest 2014; 124: 1439-1445.
45. Sheng H, Wang Y, Jin Y, et al., A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18: 846-857.
46. Polchert D, Sobinsky J, Douglas G, et al., IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755.
47. Prasanna SJ, Gopalakrishnan D, Shankar SR, et al., Pro-inflammatory cytokines, IFNgamma and TNF-alpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PloS One 2010; 5: e9016.
48. English K, Barry FP, Field-Corbett CP, et al., IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007; 110: 91-100.
49. Ren G, Zhang L, Zhao X, et al., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
50. Duijvestein M, Wildenberg ME, Welling MM, et al., Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29: 1549-1558.
51. Lee S, Szilagyi E, Chen L, et al., Activated mesenchymal stem cells increase wound tensile strength in aged mouse model via macrophages. J Surg Res 2013; 181: 20-24.
52. Badillo AT, Beggs KJ, Javazon EH, et al., Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transp 2007; 13: 412-422.
53. Rafei M, Birman E, Forner K, et al., Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799-1803.
54. Wang L, Zhao Y, Liu Y, et al., IFN-gamma and TNF-alpha Synergistically Induce Mesenchymal Stem Cell Impairment and Tumorigenesis via NFkappaB Signaling. Stem Cells 2013; 31: 1383-1395.
55. Du J, Zhou L, Chen X, et al., IFN-gamma-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol 2012; 44: 1305-1314.
56. Park H, Li Z, Yang XO, et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
57. Mojsilovic S, Krstic A, Ilic V, et al., IL-17 and FGF signaling involved in mouse mesenchymal stem cell proliferation. Cell Tissue Res 2011; 346: 305-316.
58. Huang W, La Russa V, Alzoubi A, et al., Interleukin-17A: A T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 2006; 24: 1512-1518.
59. Han X, Yang Q, Lin L, et al., Interleukin-17 enhances immunosuppression by mesenchymal stem cells. Cell Death Differ 2014; 21: 1758-1768.
60. Simmons PJ, Gronthos S, Zannettino A, et al., Isolation, characterization and functional activity of human marrow stromal progenitors in hemopoiesis. Prog Clin Biol Res 1994; 389: 271-280.
61. Wada N, Menicanin D, Shi S, et al., Immunomodulatory properties of human periodontal ligament stem cells. J Cell Physiol 2009; 219: 667-676.
62. Dominici M, Le Blanc K, Mueller I, et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
63. Muller PY, Janovjak H, Miserez AR, et al., Processing of gene expression data generated by quantitative real-time RT-PCR. BioTechniques 2002; 32: 1372-1374, 1376, 1378-1379.
64. Newland A, Russ G, Krishnan R,. Natural killer cells prime the responsiveness of autologous CD4+ T cells to CTLA4-Ig and interleukin-10 mediated inhibition in an allogeneic dendritic cell-mixed lymphocyte reaction. Immunology 2006; 118: 216-223.
65. Hope CM, Grace BS, Pilkington KR, et al., The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int 2014; 86: 175-183.
66. Nantakomol D, Nuchnoi P, Noulsri E, et al., Enumeration of the absolute CD4 T-lymphocyte count by cell-bead assay. Cytometr Part B Clin cytometr 2010; 78: 260-266.
67. Hill D, Eastaff-Leung N, Bresatz-Atkins S, et al., Inhibition of activation induced CD154 on CD4+ CD25- cells: A valid surrogate for human Treg suppressor function. Immunol Cell Biol 2012; 90: 812-821.
68. Ruitenberg JJ, Boyce C, Hingorani R, et al., Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Meth 2011; 372: 95-106.
69. Huang H, Kim HJ, Chang EJ, et al., IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: Implications for bone remodeling. Cell Death Differ 2009; 16: 1332-1343.
70. Chan WK, Lau AS, Li JC, et al., MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol 2008; 36: 1545-1555.
71. Gieseke F, Schutt B, Viebahn S, et al., Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 2007; 110: 2197-2200.
72. Zangi L, Margalit R, Reich-Zeliger S, et al., Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 2009; 27: 2865-2874.
73. Schu S, Nosov M, O'Flynn L, et al., Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16: 2094-2103.
74. Chen ZM, O'Shaughnessy MJ, Gramaglia I, et al., IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2003; 101: 5076-5083.
75. Baratelli F, Lin Y, Zhu L, et al., Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005; 175: 1483-1490.
76. Trinath J, Hegde P, Sharma M, et al., Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 2013; 122: 1419-1427.
77. Baratelli F, Lee JM, Hazra S, et al., PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2010; 2: 356-367.
78. Letourneau S, Krieg C, Pantaleo G, et al., IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123: 758-762.
79. Malek TR, Yu A, Zhu L, et al., IL-2 family of cytokines in T regulatory cell development and homeostasis. J clin Immunol 2008; 28: 635-639.
80. Bayer AL, Yu A, Malek TR,. Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunol 2007; 178: 4062-4071.
81. Moncrieffe H, Nistala K, Kamhieh Y, et al., High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol 2010; 185: 134-143.
82. Cortes JR, Sanchez-Diaz R, Bovolenta ER, et al., Maintenance of immune tolerance by Foxp3 regulatory T cells requires CD69 expression. J Autoimmun 2014; 55: 51-62.
83. Annacker O, Coombes JL, Malmstrom V, et al., Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051-1061.
84. Takeda I, Ine S, Killeen N, et al., Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004; 172: 3580-3589.
85. Tai X, Van Laethem F, Pobezinsky L, et al., Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 2012; 119: 5155-5163.
86. Baecher-Allan C, Wolf E, Hafler DA,. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622-4631.
87. Liao G, O'Keeffe MS, Wang G, et al., Glucocorticoid-Induced TNF Receptor Family-Related Protein Ligand is Requisite for Optimal Functioning of Regulatory CD4(+) T Cells. Front Immunol 2014; 5: 35.
88. Probst-Kepper M, Balling R, Buer J,. FOXP3: Required but not sufficient. The role of GARP (LRRC32) as a safeguard of the regulatory phenotype. Curr Mol Med 2010; 10: 533-539.
89. Stockis J, Colau D, Coulie PG, et al., Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009; 39: 3315-3322.
90. Maccario R, Podesta M, Moretta A, et al., Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematolgica 2005; 90: 516-525.
91. Patel SA, Meyer JR, Greco SJ, et al., Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184: 5885-5894.
92. Tasso R, Ilengo C, Quarto R, et al., Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53: 786-793.